Protocol No.: V940-014

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Principal Investigator
Bhasin, Pooja Gogia
Phase
III (Cancer Prevention)
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066

View on ClinicalTrials.gov